VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Ponatinib versus ascimininib in the third-line treatment of CML

Jorge Cortes, MD, Augusta University, Augusta, GA, compares and contrasts the use of ponatinib and asciminib in the third-line treatment of patients with chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter